Medical Devices organizations are facing growing margin pressure not because pricing teams are failing, but because commercial governance structures are increasingly fragmented. Stratence Partners explores why Commercial Transformation has become a structural operating necessity.

Consultancy.uk featured Stratence Partners following EPA Amsterdam 2026, highlighting how healthcare organizations can transform pricing pressure, fragmented data, and Gross-to-Net complexity into structured, AI-Powered commercial decision systems.

MFN is reshaping global pharma pricing. The real challenge is not price reduction, but controlling how value propagates across markets. This paper explains how leading organizations are redesigning their commercial systems to protect global asset value.

Pharma is not facing a pricing problem, but a fragmented commercial system. Discover why CEOs must now lead Commercial Transformation as an integrated operating model.

At EPA 2026, Stratence Partners will lead two executive sessions in the Pricing and AI tracks and host business-focused Poster Sessions on Commercial Transformation, AI Powered. Meet us at Booth 300A.

Ahead of EPA 2026, Stratence Partners is hosting a closed-door VIP Dinner for selected VP and C-level executives in Pricing, Market Access, Commercial and Finance governance.

EPA 2026: From Attendance to Impact The World Evidence, Pricing & Access Congress remains Europe’s most relevant gathering for senior leaders in pricing, market access, HEOR, and commercial strategy. But attendance alone does not create value. Impact comes from addressing structural weaknesses that silently erode EBIT year after year. As a global firm specialized in Commercial Transformation, AI Powered, Stratence Partners returns to EPA 2026 with two focused executive sessio

At EPA 2026, Stratence Partners will lead two executive sessions on Gross-to-Net discipline and AI-driven commercial transformation — focused on execution, governance and measurable impact.

Stratence Partners returns to EPA 2026 with two sessions that go beyond the buzzwords. Discover what we’ll be addressing — and why it matters.

Meet Stratence Partners in 2026 across 10 key global events where pricing, commercial transformation and AI-driven execution take center stage. Discover where strategy turns into measurable impact.

Stratence Partners will deliver two focused sessions at EPA 2026 addressing Gross-to-Net best practices and AI-driven commercial transformation. Join us March 3rd in Amsterdam.

Pharma transformations fail when operating models don’t evolve. Learn how Stratence Partners helps organizations embed change through governance, processes, and capability building.

Stratence Partners will be at the entrance of EPA 2026 — in Stand 300A. Come meet our global team and schedule a one-on-one with the right VP.

Stratence Partners will be at the entrance of EPA 2026 — in Stand 300A. Come meet our global team and schedule a one-on-one with the right VP.

Pharma generates data everywhere, but few companies turn it into actionable intelligence. Discover how Stratence Partners helps transform information into measurable strategic advantage.

Pharma companies succeed or fail in execution. Discover how Stratence Partners helps global pharma leaders turn strategic intent into measurable commercial performance through AI-powered transformation.

Pharma strategy must evolve to stay ahead of innovation, regulation, and pricing challenges. Discover how Stratence Partners helps global pharma companies align vision, Market Access, and execution for measurable results.

Stratence Partners will join the EPA Congress 2026 in Amsterdam with two impactful sessions led by CEO Fernando Ventureira and a full team presence at Booth 502.

Open more doors and boost market access performance through data-driven strategies and proven execution.

Redefine pharma success with Stratence Partners—strategy, pricing, and innovation that drive ROI and long-term growth.